Ohki Daisuke, Tsuji Yosuke, Hisada Hiroyuki, Nakagawa Hideki, Mizutani Satoru, Oshio Kaori, Sato Junichi, Kubota Dai, Cho Rina, Miura Yuko, Mizutani Hiroya, Sakaguchi Yoshiki, Takahashi Yu, Yakabi Seiichi, Kakushima Naomi, Yamamichi Nobutake, Ushiku Tetsuo, Fujishiro Mitsuhiro
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Next-Generation Endoscopic Computer Vision, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan.
Endosc Int Open. 2024 Mar 28;12(3):E448-E455. doi: 10.1055/a-2246-0820. eCollection 2024 Mar.
This study aimed to evaluate the relationship between sessile serrated lesion (SSL) size and the comorbidity rate of SSL with dysplasia (SSLD) and cancer in SSL (SSL-cancer). This retrospective, single-center analysis identified SSL cases that underwent endoscopic resection between January 2015 and December 2022. The prevalence of SSL, SSLD, and SSL-cancer and their annual trends were assessed. The tumor diameter was stratified as 0 to 5 mm, 6 to 9 mm, 10 to 19 mm, and ≥ 20 mm in size. Furthermore, the frequency of SSL-D/SSL-cancer was determined in each group. The prevalence of SSL was 2.9% (1328/45799). This prevalence was 1.8% (112/6192) in 2015 and 4.2% (230/5500) in 2022, indicating an increasing trend over time. A total of 1825 lesions were assessed: 1751 (96.0%), 55 (3.0%), 14 (0.8%), and 5 (0.3%) of lesions were SSL, SSL with low-grade dysplasia, SSL with high-grade dysplasia and SSL-cancer, respectively. Stratifying the SSLs by size: 0 to 5 mm, 5 to 9 mm, 10 to 19 mm, and ≥ 20 mm, SSLD and SSL-cancer rates were 2.3% (10/429), 2.4% (16/674), 5.3% (31/584), and 11.8% (16/136), respectively. SSLD and SSL-cancer were observed in 2.4% (26/1103) of small SSLs < 10 mm. In cases of SSL, the rate of SSLD and SSL-cancer increased as the lesion diameter increased. A certain rate of SSLD and SSL-cancer was observed even in small SSLs less than 5mm.
本研究旨在评估无蒂锯齿状病变（SSL）大小与SSL伴发育异常（SSLD）及SSL合并癌症（SSL-癌症）的合并症发生率之间的关系。这项回顾性单中心分析确定了2015年1月至2022年12月期间接受内镜切除的SSL病例。评估了SSL、SSLD和SSL-癌症的患病率及其年度趋势。肿瘤直径按大小分为0至5毫米、6至9毫米、10至19毫米和≥20毫米。此外，还确定了每组中SSL-D/SSL-癌症的发生率。SSL的患病率为2.9%（1328/45799）。2015年该患病率为1.8%（112/6192），2022年为4.2%（230/5500），表明随时间呈上升趋势。共评估了1825个病变：其中1751个（96.0%）、55个（3.0%）、14个（0.8%）和5个（0.3%）病变分别为SSL、低级别发育异常的SSL、高级别发育异常的SSL和SSL-癌症。按大小对SSL进行分层：0至5毫米、5至9毫米、10至19毫米和≥20毫米，SSLD和SSL-癌症的发生率分别为2.3%（10/429）、2.4%（16/674）、5.3%（31/584）和11.8%（16/136）。在<10毫米的小SSL中，2.4%（26/1103）观察到SSLD和SSL-癌症。在SSL病例中，SSLD和SSL-癌症的发生率随病变直径增加而升高。即使在小于5毫米的小SSL中也观察到一定比例的SSLD和SSL-癌症。
